Overview

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if dovitinib is an effective treatment for patients with advanced lung cancer or advanced colorectal cancer (CRC) who have progressed on anti-vascular endothelial growth factor (VEGF) treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborator:
Novartis
Treatments:
Endothelial Growth Factors
Mitogens